Inogen Continues To Generate Some Of The Best Growth In Med-Tech

Trying to figure out a fair value for a med-tech company in its high-growth phase is a really good way to look stupid, and so it is for me with Inogen (INGN). While I really like the growth story at this leading developer and manufacturer of portable oxygen concentrators, I thought valuation was already pretty generous based upon what investors typically pay for this sort of growth.

That was less than a month ago, and the shares are up another 25% as Inogen delivered a blowout first quarter and offered what looked like pretty conservative guidance for the remainder of the year. With Inogen largely setting the pace in terms of product features/capabilities and not much serious competition looming in the short term, I can understand why investors continue to bid up this fast-growing med-tech player.

Continue reading here:
Inogen Continues To Generate Some Of The Best Growth In Med-Tech